AVEO - AVEO Pharmaceuticals Inc.: The Winning Streak Continues (AVEO)
AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) traded at a new 52-week high today of $23.40. This new high was reached on above average trading volume as 265.6 million shares traded hands, while the average 30-day volume is approximately 371,000 shares.
There is potential upside of 1.2% for shares of AVEO Pharmaceuticals Inc. based on a current price of $5.88 and an average consensus analyst price target of $5.95.
In the past 52 weeks, shares of AVEO Pharmaceuticals Inc. have traded between the current low of $0.47 and a high of $7.58 and is now at $5.88.
AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States.
Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer